Sionna Therapeutics, Inc. $SION Shares Acquired by Prudential Financial Inc.

Prudential Financial Inc. increased its position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 114.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 135,185 shares of the company’s stock after acquiring an additional 72,185 shares during the period. Prudential Financial Inc. owned approximately 0.31% of Sionna Therapeutics worth $2,345,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at about $45,000. Rhumbline Advisers bought a new stake in shares of Sionna Therapeutics in the 2nd quarter worth approximately $307,000. Goldman Sachs Group Inc. acquired a new stake in Sionna Therapeutics during the first quarter valued at approximately $667,000. Charles Schwab Investment Management Inc. bought a new stake in Sionna Therapeutics during the first quarter worth approximately $676,000. Finally, Woodline Partners LP acquired a new position in Sionna Therapeutics in the first quarter worth approximately $837,000.

Insiders Place Their Bets

In other Sionna Therapeutics news, Director Ra Capital Management, L.P. sold 311,000 shares of the company’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $39.50, for a total value of $12,284,500.00. Following the transaction, the director directly owned 219,867 shares of the company’s stock, valued at $8,684,746.50. This represents a 58.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Peter A. Thompson sold 94,583 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $44.54, for a total value of $4,212,726.82. Following the sale, the director directly owned 3,610,376 shares of the company’s stock, valued at $160,806,147.04. This trade represents a 2.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,604,841 shares of company stock valued at $58,312,100 in the last three months. Company insiders own 3.90% of the company’s stock.

Analyst Upgrades and Downgrades

SION has been the subject of a number of recent research reports. Wall Street Zen downgraded Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 target price on shares of Sionna Therapeutics in a report on Monday. Raymond James Financial reiterated a “strong-buy” rating on shares of Sionna Therapeutics in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday. Finally, Jones Trading began coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $40.33.

Sionna Therapeutics Stock Performance

SION stock opened at $40.88 on Friday. The firm has a 50 day simple moving average of $35.92 and a 200 day simple moving average of $25.06. Sionna Therapeutics, Inc. has a 52 week low of $7.26 and a 52 week high of $45.00. The stock has a market cap of $1.82 billion and a P/E ratio of -8.39.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.06.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.